Investigational drug · Phase 3
OH2
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Melanoma, Solid Tumor, Gastrointestinal Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
4 still active
All registered trials
50
Any phase or sponsor naming "OH2"
First trial start
2018
Nov 22, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "OH2", any sponsor or status.
Conditions studied
As listed on its trial records.
- Melanoma
- Solid Tumor
- Gastrointestinal Cancer
- Central Nervous System Tumors
Approved drugs for the same conditions: Melanoma · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "OH2" as an intervention, largest first.
- Comparison of Postoperative Pain After Double Antibiotic Paste vs Calcium Hydroxide in Teeth With Symptomatic Apical PeriodontitisPivotal-lookingRecruiting
College of Physicians and Surgeons PakistanAcademic, hospital or other
NCT07867951 · 662 participants (planned) · Start Sep 5, 2025 · Primary completion May 5, 2026
Drug: Calcium Hydroxide (Ca(OH)2); Double Antibiotic Paste · For: Symptomatic Apical Periodontitis
Sites: Swāt, Pakistan
- Optimizing Treatment Programs for Chronic Kidney Disease-mineral and Bone Disorder and MalnutritionPivotal-lookingStatus unknown
Wenhu LiuAcademic, hospital or other
NCT02005302 · 600 participants (planned) · Start Jan 2013 · Primary completion Dec 2015
Drug: 1,25(OH)2 Vitamin D3; Vitamin D2 · For: Vitamin D Deficiency; Malnutrition
Sites: Beijing, China · 5 sites in all
- OH2 Injection in MelanomaPivotal-lookingRecruiting
Binhui Biopharmaceutical Co., Ltd.Industry
NCT05868707 · 340 participants (planned) · Start Mar 8, 2023 · Primary completion Mar 2026
Drug: OH2; Salvage chemotherapy or best supportive care · For: Melanoma
Sites: Beijing, China; Chongqing, China; Fuzhou, China · 30 sites in all
Binhui Biopharmaceutical Co., Ltd.Industry
NCT03866525 · 300 participants (planned) · Start Apr 2, 2019 · Primary completion Aug 30, 2025
Drug: OH2 injection, with or without irinotecan or HX008 · For: Solid Tumor; Gastrointestinal Cancer
Sites: Beijing, China
- Efficacy of Vitamin D2 to Treat Chronic Kidney Disease Mineral and Bone DisorderPivotal-lookingCompleted
Dongliang Zhang, MDAcademic, hospital or other
NCT01633853 · 204 participants · Start Jul 2012 · Primary completion Sep 2015
Drug: Vitamin D2; 1,25(OH)2 Vit D3 · For: Vitamin D Deficiency
Sites: Beijing, China
- Regenerative Treatment of Traumatized Immature Permanent Incisors With Pulp NecrosisPivotal-lookingStatus unknown
Karolinska InstitutetAcademic, hospital or other
NCT04000854 · 180 participants (planned) · Start Feb 19, 2019 · Primary completion Dec 19, 2023
Drug: Calcium hydroxide (Calacept) · For: Regenerative Endodontics in Traumatized Immature Teeth
Sites: Stockholm, Sweden
- Calcium Hydroxide, Mineral Trioxide Aggregate and Biodentine (Trademark) as Direct Pulp Capping of Permanent TeethPivotal-lookingCompleted
Universidad de los Andes, ChileAcademic, hospital or other
NCT02492841 · 169 participants · Start Apr 2014 · Primary completion Apr 2016
Drug: Mineral trioxide aggregate; Calcium hydroxide and 1 more · For: Caries; Dental Pulp Exposure
Sites: Santiago, Chile
- Multiple-Visit RCT in Teeth With SAP: Interappointment Dressing or Not?Pivotal-lookingActive, not recruiting
Aristotle University Of ThessalonikiAcademic, hospital or other
NCT06447519 · 110 participants (planned) · Start Sep 12, 2024 · Primary completion Sep 12, 2026
Drug: Ca(OH)2 as intracanal medicament · For: Endodontically Treated Teeth; Calcium Hydroxide
Sites: Thessaloniki, Greece
- A Study of LP002 for the Treatment of Patients With Malignant Digestive System NeoplasmsStatus unknown
Taizhou HoudeAoke Biomedical Co., Ltd.Industry
NCT04755543 · 94 participants (planned) · Start Jun 17, 2019 · Primary completion Jun 30, 2021
Drug: LP002; Cisplatin and 2 more · For: Digestive System Neoplasms
Sites: Beijing, China; Zhengzhou, China; Wuhan, China · 6 sites in all
- Long-term Evaluation of Direct Pulp CappingStatus unknown
Jordan University of Science and TechnologyAcademic, hospital or other
NCT03403985 · 80 participants (planned) · Start Jun 1, 2017 · Primary completion Jun 28, 2017
Drug: Calcium Hydroxide (Ca(OH)2); Mineral Trioxide Aggregate · For: Dental Pulp Capping; Dental Caries Extending to Pulp
Sites: Irbid, Jordan
Newest research
PubMed records naming it or its code names, newest first.
- Unveiling hydration pathways and kinetics of red mud-derived cementitious materials via tailored alkali activation systems.
Yan X, Ma X, Li D, et al. · Waste Manag 2027
- Narrowing the pH-Dependent HER Activity Gap via Synergistic Heteronuclear Dual-Single-Atom Sites and Compressive Strain in Sub-1.6 nm High-Entropy Alloy Clusters.
Zhang Y, Yuan Q · Inorg Chem 2026
- Refining AMOEBA Electrostatics for d-Glucose and 14-Linked d-Glucose Oligosaccharides.
Newman LA, Ophof R, Vaissier Welborn V · J Chem Inf Model 2026
- Simulating Chemical Reaction Dynamics Using Sample-Based Quantum Diagonalization: A Quantum-Centric Supercomputing Approach.
Kumar S, Ghosh K, Kumar D, et al. · J Am Chem Soc 2026
- A Programmable KillSwitch in NewTAML Catalysts Decouples Oxidative Reactivity from Catalyst Lifetime.
Chakraborty D, Schafer MG, Ma X, et al. · J Am Chem Soc 2026
- Air- and Thermally Stable Organometallic Fe(VI) Nitrides Enabled by a Tripodal Mesoionic Carbene Ligand: Access to a Water-Coordinated Fe(VI) Nitrido Complex.
Zhang Z, Jori N, Scheurer A, et al. · J Am Chem Soc 2026
Also in development for Melanoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- IBI363Phase 37 trials
Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer
- PucotenlimabHX008Phase 36 trials
Lepu Biopharma Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Melanoma, Hepatocellular Carcinoma
- CeralasertibAZD6738Phase 35 trials
AstraZeneca · Melanoma, Advanced or Metastatic NSCLC, Non-Small Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.